The importance of considering alternative or combination strategies for lowering LDL-C

International Journal of Cardiology

Volumn 136, Issue 2, 2009, Pages 115-119

  Koh, Kwang Kon ^a   Quon, Michael J ^b  

^a Gachon University College of Medicine   (South Korea)

^b National Institutes of Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; DRUG FATALITY; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; STROKE;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; HUMANS; HYPERCHOLESTEROLEMIA; RISK FACTORS;

EID: 67650862790     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.03.035     Document Type: Editorial

References (24)

1. Steinberg D. The statins in preventive cardiology. N Engl J Med 359 (2008) 1426-1427
2. Steinberg D., Glass C.K., and Witztum J.L. Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation 118 (2008) 672-677
3. Alsheikh-Ali A.A., Maddukuri P.V., Han H., and Karas R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50 (2007) 409-418
4. Rossebø A.B., Pedersen T.R., Boman K., et al., SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359 (2008) 1343-1356
5. La Rosa J.C., Grundy S.M., Waters D.D., et al. Treating to New Targets (TNT) Investigators. intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
6. Jacobs D., Blackburn H., Higgins M., et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 86 (1992) 1046-1060
7. D'Agostino R.B., Belanger A.J., Kannel W.B., and Higgins M. Role of smoking in the U-shaped relation of cholesterol to mortality in men. The Framingham study. Am J Epidemiol 141 (1995) 822-827
8. Wannamethee G., Shaper A.G., Whincup P.H., and Walker M. Low serum total cholesterol concentrations and mortality in middle aged British men. BMJ 311 (1995) 409-413
9. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., and White C.M. Statins and cancer risk: a meta-analysis. JAMA 295 (2006) 74-80
10. Alsheikh-Ali A.A., Trikalinos T.A., Kent D.M., and Karas R.H. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 52 (2008) 1141-1147
11. Ridker P.M., Danielson E., Fonseca F.A., et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
12. Corti R., Fuster V., Fayad Z.A., et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 46 (2005) 106-112
13. Wanner C., Krane V., März W., et al. German Diabetes and Dialysis Study Investigators. atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
14. Barter P., Gotto A.M., LaRosa J.C., et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
15. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110 (2004) 3687-3692
16. Koh K.K., Quon M.J., Han S.H., et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 45 (2005) 1088-1093
17. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of patients with combined hyperlipidemia. J Am Coll Cardiol 45 (2005) 1649-1653
18. Koh K.K., Han S.H., and Quon M.J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 46 (2005) 1978-1985
19. Han S.H., Quon M.J., Kim J., and Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 49 (2007) 531-538
20. Rodriguez-Porcel M., Lerman L.O., Herrmann J., Sawamura T., Napoli C., and Lerman A. Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function. Arterioscler Thromb Vasc Biol 23 (2003) 885-891
21. Kim J., Montagnani M., Koh K.K., and Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113 (2006) 1888-1904
22. Koh K.K., and Quon M.J. Combination therapy for treatment or prevention of atherosclerosis. Hypertension 52 (2008) e18
23. Koh K.K., and Quon M.J. Targeting converging therapeutic pathways to overcome hypertension. Int J Cardiol 132 (2009) 297-299
24. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150